Showing results (211-220 of 219) with videos related to
Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 219 results.
European Urology|June 1, 2022
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02Arlene O Siefker-Radtke, Daniel C Cho, Adi Diab, et al.Circulation Research|February 19, 2016
Cardiac Stem Cell Treatment in Myocardial Infarction: A Systematic Review and Meta-Analysis of Preclinical StudiesPeter Paul Zwetsloot, Anna Maria Dorothea Végh, Sanne Johanna Jansen of Lorkeers, et al.Plos Biology|November 12, 2015
Correction: Risk of Bias in Reports of In Vivo Research: A Focus for ImprovementMalcolm R Macleod, Aaron Lawson McLean, Aikaterini Kyriakopoulou, et al.Journal for Immunotherapy of Cancer|April 21, 2022
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 studyNizar M Tannir, Daniel C Cho, Adi Diab, et al.Future Oncology (London, England)|January 25, 2022
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrenceAlexander Mm Eggermont, Paolo A Ascierto, Nikhil I Khushalani, et al.Plos Biology|May 21, 2019
Animal models of chemotherapy-induced peripheral neuropathy: A machine-assisted systematic review and meta-analysisGillian L Currie, Helena N Angel-Scott, Lesley Colvin, et al.Plos Biology|October 14, 2015
Risk of Bias in Reports of In Vivo Research: A Focus for ImprovementMalcolm R Macleod, Aaron Lawson McLean, Aikaterini Kyriakopoulou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2021
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic MelanomaAdi Diab, Scott S Tykodi, Gregory A Daniels, et al.Pain|December 20, 2015
Ensuring transparency and minimization of methodologic bias in preclinical pain research: PPRECISE considerationsNick A Andrews, Alban Latrémolière, Allan I Basbaum, et al.Pageof 22